GoldenGolden
Advanced Search
Qiagen

Qiagen

Qiagen is a biotechnology company providing sampling and assay technologies for molecular diagnostics and applied testing for use in the private and public sectors. The company is headquartered in Venlo, Netherlands and was founded in 1984 by Metin Colpan.

Qaigen is a biotechnology company headquartered in Venlo, Netherlands and founded by Metin Colpan in 1984. Qaigen is a publicly traded company on the New York Stock and Frankfurt Prime Standard exchanges. Qiagen has around 4,700 employees in over 35 locations in 25 countries around the world.

Qaigen supplies technologies that help private and public scientists perform molecular diagnostics and applied testing in their experiments and//or tests. Their products are used for research and testing in several industries which include: healthcare, veterinary practices, forensics, food safety, pharmaceutical, bioinformatics, biotechnology, and life science.

Timeline

November 29, 1984
Qiagen was founded by Metin Colpan.

Acquisitions

People

Name
Role
LinkedIn

Abdul Muqeet

Employee

Ada Kim

Employee

Adam Abdool

Employee

Alexandra Lanicca

Employee

Alexandru-Valentin Pavelescu

Employee

Ali Murat Kaya

Employee

Alison Zartarian

Employee

Andy Wende

Employee

Angela Long

Employee

Anika Joecker

Employee

Anita Suresh

Employee

Anja Lykkebak

Employee

Annete Koch

Senior Vice President and Chief Human resources Officer

Anosheh Amery

Employee

ANTONELLA CAPIZZI ACC, Chartered-MCIPD, MA-HRM, MSSc

Employee

Anu Jayaraman

Employee

Arianna Morosetti

Employee

Attila Mihaly Balazs

Employee

Attila-Mihaly Balazs (Grey Panther)

Employee

Austin Waltz

Employee

Ben Turner

Employee

Benedikt von Braunmühl

Employee

Beth Lewis

Employee

bhakti shah

Employee

Bharath Hegde

Employee

Page 1 of 7
...

Further reading

Title
Author
Link
Type
Date

History of Qiagen N.V. - FundingUniverse

International Directory of Company Histories, Vol. 39. St. James Press, 2001.

Web

QIAGEN and NeuMoDx Announce Strategic Partnership to Offer Next-Generation Systems for Fully Integrated Molecular Diagnostic Testing

Business Wire

Web

Qiagen launches molecular analysis panel for GI disorders in Europe

Medical Device Network

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Andrea Park
July 12, 2021
FierceBiotech
In comparison to an original prediction of about 18% to 20% sales growth for the whole year, Qiagen is now expecting to bring in a much more modest 12% bump in year-over-year sales.
Alex Keown
June 30, 2021
BioSpace
The two companies will collaborate to market Verogen's forensically validated NGS workflows alongside QIAGEN's full range of forensic-grade chemistries and sample prep automation.
June 30, 2021
BioSpace
Statement from Davidson Kempner regarding Qiagen - read this article along with other careers information, tips and advice on BioSpace
Global Market Insights Inc.
June 28, 2021
www.prnewswire.com:443
/PRNewswire/ -- According to the latest report "Precision Medicine Market by Type (Diagnostics, Therapeutics), Application (Oncology, CNS, Immunology,...
Qiagen
June 18, 2021
www.prnewswire.com:443
/PRNewswire/ -- Desde a descoberta do SARS-CoV-2 nos dejetos de pessoas infectadas, o monitoramento do vírus em águas residuais tem sido uma medida essencial...
QIAGEN
February 26, 2021
www.prnewswire.com:443
/PRNewswire/ -- Às vésperas do mês de março, quando acontece a campanha global da Organização Mundial da Saúde (OMS) "Unidos Para Acabar com a Tuberculose" e a...
INOVIO Pharmaceuticals, Inc.
February 24, 2021
www.prnewswire.com:443
/PRNewswire/ -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and INOVIO Pharmaceuticals (NASDAQ: INO) today announced an extension of their partnership...
Davidson Kempner
December 15, 2020
www.prnewswire.com:443
/PRNewswire/ -- Constructive and Substantive Engagement with Qiagen N.V. ("the Company") Davidson Kempner has enjoyed considerable engagement with the...
Conor Hale
December 7, 2020
FierceBiotech
Qiagen has launched a new COVID-19 blood test designed for researchers trying to uncover the intricacies of the body's immune response to the novel coronavirus.
October 15, 2019
WebWire
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced the launch of innovative new technologies for faster, simpler library preparation for next-generation sequencing (NGS) in the growing field of RNA research. QIAGEN is showcasing its industry-leading portfolio of universal NGS solutions at ASHG 2019, the annual meeting of the American Society of Human Genetics, from October 15-19 in Houston. Attendees will also get the chance to experience QIAGEN's new GeneGlobe Design & Analy...
May 17, 2019
WebWire
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Inovio Pharmaceuticals Inc. (NASDAQ: INO) announced a collaboration to co-develop a companion diagnostic to guide clinical decision-making for the use of Inovio's DNA-based immunotherapy to treat cervical dysplasia caused by human papillomavirus (HPV). The Precision Medicine partnership focuses on Inovio's VGX-3100, a late-stage investigational product candidate with potential to become the first treatment for HPV infection...

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.